866-997-4948(US-Canada Toll Free)

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 198 Pages

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H2 2017, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 16, 1, 22 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure)-Overview 8
Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Chronic Kidney Disease (Chronic Renal Failure)-Companies Involved in Therapeutics Development 29
Allena Pharmaceuticals Inc 29
Angion Biomedica Corp 29
apceth Biopharma GmbH 30
Astellas Pharma Inc 30
AstraZeneca Plc 31
Bayer AG 31
Boehringer Ingelheim GmbH 32
Boryung Pharmaceutical Co Ltd 32
Cellmid Ltd 33
Chugai Pharmaceutical Co Ltd 33
Corvidia Therapeutics 34
CTI BioPharma Corp 34
Evotec AG 35
Gilead Sciences Inc 35
GNI Group Ltd 36
Lupin Ltd 36
Merck & Co Inc 37
Navya Biologicals Pvt Ltd 37
Nippon Zoki Pharmaceutical Co Ltd 38
Novartis AG 38
OPKO Health Inc 39
Otsuka Holdings Co Ltd 39
Prolong Pharmaceuticals LLC 40
ProMetic Life Sciences Inc 40
Reata Pharmaceuticals Inc 41
Relypsa Inc 41
Resverlogix Corp 42
Sarfez Pharmaceuticals Inc 42
Spotlight Innovation Inc 43
Taisho Pharmaceutical Holdings Co Ltd 43
Toray Industries Inc 44
Tricida Inc 44
Unity Biotechnology Inc 44
Vascular BioSciences 45
VESSL Therapeutics Ltd 45
Vicore Pharma AB 46
Chronic Kidney Disease (Chronic Renal Failure)-Drug Profiles 47
ALLN-346-Drug Profile 47
ambrisentan-Drug Profile 48
ANG-3070-Drug Profile 51
ANG-3281-Drug Profile 52
ANG-3586-Drug Profile 53
ANG-4201-Drug Profile 54
apabetalone-Drug Profile 55
AS-2444697-Drug Profile 69
bardoxolone methyl-Drug Profile 70
BAY-1101042-Drug Profile 77
BI-655088-Drug Profile 78
BKE-001-Drug Profile 79
BMP-7-Drug Profile 80
C-21-Drug Profile 82
CAB-101-Drug Profile 86
calcium succinate-Drug Profile 88
CAR Peptide-Drug Profile 89
cardiotoxin-Drug Profile 90
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders-Drug Profile 91
COR-001-Drug Profile 93
CTA-091-Drug Profile 94
dapagliflozin propanediol-Drug Profile 95
Drug for Kidney Diseases-Drug Profile 104
Drug to Inhibit Chymase for Chronic Kidney Disease-Drug Profile 105
EOS-789-Drug Profile 106
F-351-Drug Profile 107
KBP-5074-Drug Profile 109
MK-3866-Drug Profile 111
Monoclonal Antibodies to Inhibit KITLG for Genito Urinary System and Sex Hormones, Immunology and Respiratory Diseases-Drug Profile 112
MultiGeneGraft-Drug Profile 113
NAV-003-Drug Profile 114
NZ-419-Drug Profile 115
pacritinib-Drug Profile 116
patiromer sorbitex calcium-Drug Profile 130
PBI-4050-Drug Profile 134
Recombinant Plasma Gelsolin Replacement for Renal Disease-Drug Profile 143
Sanguinate-Drug Profile 144
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism-Drug Profile 147
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease-Drug Profile 148
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease-Drug Profile 149
Small Molecules for Chronic Kidney Disease-Drug Profile 150
Small Molecules for Chronic Kidney Disease-Drug Profile 151
Small Molecules to Inhibit CYP11B2 for Chronic Kidney Disease-Drug Profile 152
Small Molecules to Inhibit LGALS3 for Cardiovascular, Respiratory and Genito Urinary System Disorders-Drug Profile 153
SP-20103-Drug Profile 154
SPR-494-Drug Profile 155
Stem Cell Therapy for Chronic Kidney Disease-Drug Profile 156
Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease-Drug Profile 157
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease-Drug Profile 158
tesidolumab-Drug Profile 159
tolvaptan-Drug Profile 161
torsemide ER-Drug Profile 166
TPX-200-Drug Profile 167
TRC-101-Drug Profile 168
TS-143-Drug Profile 170
verinurad-Drug Profile 171
Vida-5-Drug Profile 174
VS-105-Drug Profile 175
Wnt-001-Drug Profile 176
YS-1402-Drug Profile 177
Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects 178
Chronic Kidney Disease (Chronic Renal Failure)-Discontinued Products 181
Chronic Kidney Disease (Chronic Renal Failure)-Product Development Milestones 182
Featured News & Press Releases 182
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 193
Disclaimer 194

List of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Allena Pharmaceuticals Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Angion Biomedica Corp, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by apceth Biopharma GmbH, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Astellas Pharma Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by AstraZeneca Plc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Bayer AG, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Boehringer Ingelheim GmbH, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Cellmid Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Corvidia Therapeutics, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by CTI BioPharma Corp, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Evotec AG, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Gilead Sciences Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by GNI Group Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Lupin Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Merck & Co Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Navya Biologicals Pvt Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Novartis AG, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by OPKO Health Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Otsuka Holdings Co Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Prolong Pharmaceuticals LLC, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by ProMetic Life Sciences Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Reata Pharmaceuticals Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Relypsa Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Resverlogix Corp, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Spotlight Innovation Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Toray Industries Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Tricida Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Unity Biotechnology Inc, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Vascular BioSciences, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by VESSL Therapeutics Ltd, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Vicore Pharma AB, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects, H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects, H2 2017 (Contd..1), H2 2017
Chronic Kidney Disease (Chronic Renal Failure)-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *